David M. Cross - Concepedia

Author

David M. Cross

Heptares Therapeutics (United Kingdom)

Also Known As

D Cross, D. M. CROSS, D. M. Cross, D.M. Cross, DAVID M. CROSS, David M. Cross

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Heptares Therapeutics (United Kingdom)Monash University Pfizer (United States)Leiden University Medical Center Pfizer (United Kingdom)

About

David M. Cross is an author at Heptares Therapeutics (United Kingdom) specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	740
2	Cell Biology	5	5	617
3	Biochemistry	4	4	376
4	Natural Sciences	3	3	366
5	Health Sciences	1	1	10

David M. Cross

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Identification of <i>N</i>-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design Paul G. Wyatt, Andrew Woodhead, Valério Berdini, Journal of Medicinal Chemistry	2008	337
Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity Steven Howard, Valério Berdini, John A. Boulstridge, Journal of Medicinal Chemistry Drug TargetPyrazol-4-yl UreaClinical CandidateAurora BChemical Biology	2008	329
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines Matthew Squires, Ruth E. Feltell, Nicola G. Wallis, Molecular Cancer Therapeutics Chemoprevention StrategyCancer BiologyTumor BiologyCdk InhibitorsAnti-cancer Agent	2009	171
From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease Alastair Brown, Sophie J. Bradley, Fiona H. Marshall, Cell Molecular PharmacologyNeurodegenerative DiseasesAlzheimer's DiseaseMedicineMechanism Of Action	2021	87
The heat shock protein 90 inhibitor, <scp>AT</scp>13387, displays a long duration of action <i>in vitro</i> and <i>in vivo</i> in non‐small cell lung cancer Brent Graham, Jayne Curry, Tomoko Smyth, Cancer Science Tumor XenograftsChemoprevention StrategyMolecular BiologyCancer BiologyTumor Biology	2011	80
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension Keith Owen, David M. Cross, Mazin Derzi, Regulatory Toxicology and Pharmacology HypertensionPulmonary Arterial HypertensionPulmonary CirculationMedicinePhysiology	2012	26
Adenosine triphosphate as an indicator of cellular toxicity In vitro R.B. Kemp, David M. Cross, R.W.J. Meredith Food and Chemical Toxicology Signal TransductionBiochemistryNatural SciencesApoptosisAdenosine Triphosphate	1986	23
Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study C. J. G. Bakker, Tim Tasker, Jan Liptrot, Alzheimer s Research & Therapy	2021	16
First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub>‐receptor partial agonist for the treatment of dementias C. J. G. Bakker, Tim Tasker, Jan Liptrot, British Journal of Clinical Pharmacology	2020	15
Comparison of cell death and adenosine triphosphate content as indicators of acute toxicity in vitro R.B. Kemp, David M. Cross, R.W.J. Meredith Xenobiotica Sodium ChlorideApoptosisCell DeathCellular PhysiologyToxicological Mechanism	1988	14

Page 1